VistaGen Therapeutics (VTGN) Q3 2025 earnings summary

Executive summary

• Advanced clinical pipeline with five intranasal pherine product candidates, including fasedienol (SAD), itruvone (MDD), PH80 (VMS and PMDD), PH15 (cognitive impairment), and PH284 (cancer cachexia), all showing positive clinical data and differentiated safety profiles.

• Lead asset fasedienol is in Phase 3 trials (PALISADE-3 and PALISADE-4) for acute treatment of social anxiety disorder, with Fast Track designation and top-line results expected in 2025.

• Additional programs include itruvone for major depressive disorder and PH80 for menopausal hot flashes, both progressing toward further clinical development.

• Positive Phase 2A results reported for PH284 in cancer cachexia, expanding the breadth of the pipeline.

• The company has not yet achieved revenue-generating status from product sales and expects continued operating losses as development progresses.

Financial highlights

• Research and development expenses rose to $11.3 million for Q3 FY2025, up from $4.5 million year-over-year, and totaled $29.2 million for the nine months ended December 31, 2024, up from $12.6 million year-over-year.

• General and administrative expenses were $4.0 million for the quarter, up from $3.8 million year-over-year, and $12.8 million for the nine months ended December 31, 2024.

• Net loss attributable to common stockholders was $14.1 million for the quarter, compared to $6.4 million in the prior year, and $37.8 million for the nine months ended December 31, 2024, compared to $19.8 million in the prior year.

• Cash, cash equivalents, and marketable securities totaled $88.6 million as of December 31, 2024.

• Revenue for the quarter was $234,000, down from $411,000 year-over-year.

Outlook and guidance

• Confident in delivering top-line data from PALISADE-3 and PALISADE-4 in 2025, with no anticipated delays.

• Preparing for Phase 2B development of itruvone in the U.S. and IND submission for PH80.

• Current cash resources are expected to fund planned operations for more than twelve months from the financial statement issuance date.

• The company anticipates continued operating losses and negative cash flows as it advances its clinical pipeline.

• Management expects R&D and G&A expenses to increase as clinical programs advance and headcount grows.